**Sup Table 1.** Characteristics of patients according to the reason for the initial IFX discontinuation.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **Secondary loss of response**  **N = 48** | **Intolerance**  **N = 21** | **p-value** |
| **Male** | N (%) | 20 (42) | 7 (33) | 0.51 |
| **Age** (Years) | Median (IQR) | 34 (26-43) | 35 (28-41) | 0.37 |
| **Smoking**  Active  Previous | N (%)  N (%) | 16 (34)  13 (28) | 6 (29)  3 (14) | 0.30 |
| **Disease duration** (Years) | Median (IQR) | 8.7 (6.6-13.8) | 14.1 (11.8-20.8) | 0.005 |
| **Illness behaviour**  B1 (non-stricturing, non penetrating)  B2 (stricturing)  B3 (penetrating) | N (%)  N (%)  N (%) | 15 (31)  18 (38)  14 (29) | 8 (38)  10 (48)  5 (24) | 0.58  0.43  0.65 |
| **CD location**  L1 (ileal)  L2 (colonic)  L3 (ileocolonic)  Upper Gastrointestinal Disease | N (%)  N (%)  N (%)  N (%) | 15 (31)  10 (21)  25 (52)  6 (12) | 6 (29)  6 (29)  11 (52)  0 (0) | 0.82  0.70  0.98  0.22 |
| **Perianal lesions** | N (%) | 24 (50) | 13 (62) | 0.36 |
| **History of intestinal resection for CD** | N (%) | 19 (40) | 8 (38) | 0.91 |
| **Family history of IBD** | N (%) | 14 (29) | 6 (29) | 1.00 |
| **Duration between initial discontinuation and IFX restart (Months)** | Median (IQR) | 34.5 (17.2-62.0) | 76.2 (33.1-101.4) | 0.007 |
| **CDAI at inclusion** | Median (IQR) | 263 (226-349) | 244 (175-421) | 0.99 |
| **CRP at inclusion (mg/L)** | Median (IQR) | 14.4 (6.6-31) | 10.2 (5-31) | 0.68 |
| **Fecal calprotectin at inclusion (μg/g)** | Median (IQR) | 1084 (476-1800) | 1190 (106-1573) | 0.68 |
| **Concomitant treatments**  Corticosteroids  Immunosuppressants | N (%)  N (%) | 15 (31)  5 (10) | 8 (38)  1 (5) | 0.59  0.66 |